3.2. Safety Evaluation
treatment-emergent adverse, death
ADVERSE EVENTS
Four treatment-emergent adverse events (TEAEs) were observed in 2 out of 10 participants (20.00%) who received EG-Mirotin. None of those TEAEs were related to the investigational drug and did not result in drug discontinuation. No adverse events leading to death were reported.